Legislation: Mozambique’s legal framework for drug studies is rooted in the Law No. 10/2007 of 8 March, which establishes the functions of the MCZ. Understanding this law is key to compliance.

International Guidelines: MCZ adheres to International Council for Harmonisation (ICH) guidelines, particularly ICH-GCP (Good Clinical Practice), which outlines the ethical and scientific quality of trials.

Regional Regulations: Mozambique is part of the Southern African Development Community (SADC), and collaboration with regional partners may provide additional insights into best practices.

To stay updated, check the official MCZ website for any changes or updates to regulations impacting clinical trials.

Step 2: Preparing the Clinical Trial Dossier

Once you understand the regulatory framework, the next step involves preparing the clinical trial dossier. This dossier must be comprehensive and align with both local and international expectations. Key components to include are:

• Protocol Summary: Detail the objectives, methodology, and design of the study. Ensure adherence to ICH-GCP guidelines and explicitly state how you will monitor safety and efficacy.
• Investigator’s Brochure: A document that provides in-depth information about the drug or intervention under investigation, including preclinical and clinical data.
• Informed Consent Forms: Draft clear consent forms that are ethically sound and understandable to the patient population involved in the trial.
• Site Information: Provide information about the trial sites and qualifications of the principal investigators.
• Ethics Committee Approval: Include approval letters from the relevant ethics committees. This is crucial in demonstrating ethical compliance.

Ensure that the dossier is structured according to the eCTD (electronic Common Technical Document) format for ease of review. This structure is becoming an international standard and facilitates submission processes.

Step 3: Submission of the Clinical Trial Application (CTA)

Having prepared a thorough clinical trial dossier, the subsequent step is to submit the Clinical Trial Application (CTA) to the MCZ. Submission requires careful attention to detail. The key actions include:

• Filing the Application: Submit the application via the electronic platform established by the MCZ. Ensure all components of the dossier are included to avoid delays.
• Application Fees: Be aware that there may be fees associated with the application. Consult the MCZ fee schedule to ensure timely processing.
• Response to Queries: Anticipate potential queries from the MCZ regarding your submission. Preparing for potential back-and-forth is essential for a successful application process.
• Monitoring Timelines: According to MCZ guidelines, the review process can take up to 30 days, but this can vary based on the trial’s complexity and MCZ’s current workload. Maintain communication with the agency for updates.

Step 4: Ethics Review Process

Upon submission of the CTA, the trial will undergo an ethics review. This stage is critical for ensuring that the trial aligns with ethical standards, particularly concerning participant safety and informed consent. Steps involved include:

• Ethics Committee Submission: Along with the CTA, submit your protocol and informed consent documents to an independent Ethics Committee (EC) for review.
• Review Timeline: The ethics review may take up to 4 weeks. Engage with the ethics committee to understand their expectations and any necessary amendments.
• Revisions: Be prepared to make revisions based on feedback from the ethics committee. Their primary concern will be the welfare of participants and the integrity of the study.
• Final Approval: Obtain final ethical approval prior to commencing any investigational activities. This approval is mandatory for legally conducting the trial.

Documentation of this process is necessary, as it serves as evidence of compliance with ethical standards.

Step 5: Commencing the Clinical Trial

With regulatory and ethical approvals in place, your team can now commence the clinical trial. This step requires meticulous planning and execution. Key actions include:

• Site Initiation: Organize an initiation meeting with the clinical trial sites to ensure that all personnel are trained on the protocol and their respective roles.
• Patient Recruitment: Implement methods for recruiting participants that are ethical and compliant with consent protocols. This is vital for data quality and participant safety.
• Data Collection: Utilize robust systems for data collection, ensuring compliance with ICH-GCP standards. This includes electronic data capture systems and proper recording mechanisms.
• Monitoring and Reporting: Establish monitoring processes to guarantee adherence to the protocol. This includes continuous evaluation of participant safety and adverse event reporting.
• Documentation: Keep accurate and comprehensive records, as this represents the foundation for trial validity and regulatory compliance.

During this phase, continuous interaction with regulatory bodies and the ethics committee may be necessary to report on progress and any unforeseen issues.

Step 6: Post-Trial Responsibilities and Reporting

After the completion of the clinical trial, regulatory compliance does not cease. It is critical to fulfill post-trial responsibilities, which include:

• Final Report Submission: Prepare and submit a comprehensive final clinical study report (CSR) to the MCZ detailing findings and outcomes related to the trial.
• Publication of Results: Ethical guidelines require that the results of the trial be published, regardless of whether the outcomes were positive or negative. Transparency is essential.
• Pharmacovigilance: Continue monitoring and reporting adverse events even after the trial concludes. This commitment to patient safety remains paramount.
• Regulatory Follow-Up: Engage with local authorities to ensure compliance with subsequent requirements or requests for additional data related to the drug being studied.

Documentation during this phase should reflect all findings, decisions made, and correspondence with regulatory bodies to ensure a transparent post-trial process.

Final Remarks

Successfully navigating the clinical trial authorization and ethics review in Mozambique requires diligence, attention to procedural detail, and consistent compliance with regulatory expectations. By following the outlined steps, regulatory affairs professionals can facilitate a smoother trial process while upholding the highest standards of public health and safety. This guide serves as a foundational tool for ensuring compliance throughout all phases of clinical research in Mozambique.

For more detailed guidance and country-specific updates, consult the World Health Organization (WHO) and the official MCZ website. With the landscape constantly evolving, staying informed will be key to successful medical affairs in this emerging market.